The Mutaflor – Escherichia coli strain Nissle 1917, serotype 06:K5:H1
Authors:
M. Lukáš
Authors‘ workplace:
Klinické a výzkumné centrum pro střevní záněty, ISCARE a 1. LF UK v Praze a Ústav klinické biochemie a laboratorní diagnostiky, 1. LF UK v Praze
Published in:
Gastroent Hepatol 2013; 67(2): 170-171
Category:
Drug Profile
Sources
1. Nissle A. Uber die Grundlagen einer neuen ursachlichen Bekampfung der pathologischen Darmflora. Dtsch Med Wochenschr 1916; 42: 1181–1184.
2. Nissle A. Weiteres uber Grundlagen und Praxis der Mutaflorbehandlung. Dtsch Med Wochenschr 1925; 44: 1809–1813.
3. Pelech T, Frič P, Fixa B et al. Srovnání Mutafloru a mesalazinu v udržovací léčbě u neaktivní idiopatické proktokolitidy. Prakt Lék 1998; 78: 1998.
4. Rembacken BJ, Snelling AM, Hawkey PM et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999; 354(9179): 635–639.
5. Kruis W, Frič P, Pokrotniekes J et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53(11): 1617–1623.
6. Cukrowska B, Lodinova-Iadnikova R, Enders C et al. Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917. Scand J Immunol 2002; 55(2): 204–209.
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
![Issue 2](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/635b8674507f84ec3821e6c1c0ff87b0.jpeg)
2013 Issue 2
Most read in this issue
- Danis oesophageal stent in treatment of variceal bleeding
- The Mutaflor – Escherichia coli strain Nissle 1917, serotype 06:K5:H1
- Multifocal hepatocellular carcinoma imitating hepatal cirrhosis
- Metastatic affection of small intestine as the first symptom of generalization of malignant melanoma